Generic analysis of FDA regulatory improvements and biotech investment outlook

The passage contains only broad, publicly known statements about FDA processes and biotech investment trends, without any specific actors, transactions, or novel allegations. It offers no actionable l Describes FDA initiatives like Breakthrough Therapy, Accelerated Approval, and Priority Review. Notes increase in NDAs approved in 2012 versus prior years. Highlights perceived favorable investment e